EODData

LSE, 0O14: Merck Kgaa

16 Oct 2025
LAST:

111.2

CHANGE:
 5.95
OPEN:
119.0
HIGH:
119.2
ASK:
158.1
VOLUME:
165.2K
CHG(%):
5.08
PREV:
117.1
LOW:
108.0
BID:
154.9
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
16 Oct 25119.0119.2108.0111.2165.2K
15 Oct 25116.0117.6116.0117.135.6K
14 Oct 25117.0117.2114.9115.12.3K
13 Oct 25116.4117.7116.0117.64K
10 Oct 25118.5119.8116.3116.52.8K
09 Oct 25120.2120.9118.0118.33.9K
08 Oct 25118.8120.7117.6120.633.7K
07 Oct 25120.0120.3118.5119.332.7K
06 Oct 25121.3122.2120.0120.22.3K
03 Oct 25118.1121.5117.6120.765.5K

COMPANY PROFILE

Name:Merck Kgaa
About:Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Address:Frankfurter Strasse 250, Darmstadt, Germany, 64293
Website:https://www.merckgroup.com/en
ISIN:DE0006599905
LEI:529900OAREIS0MOPTW25

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

TECHNICAL INDICATORS

MA5:115.503.9%
MA10:117.645.8%
MA20:113.972.5%
MA50:111.190.0%
MA100:111.520.3%
MA200:120.978.8%
STO14:26.01
RSI14:56.24
WPR14:-70.97
MTM14:3.88
ROC14:0.04 
ATR:4.12 
Week High:120.858.7%
Week Low:108.002.9%
Month High:122.209.9%
Month Low:105.258.8%
Year High:168.3551.4%
Year Low:100.9010.2%
Volatility:31.01 

RECENT SPLITS

Date Ratio
30 Jun 20142-1

RECENT DIVIDENDS

Date Amount
28 Apr 2025$2.20
29 Apr 2024$2.20
02 May 2023$2.20
25 Apr 2022$1.85
26 Apr 2021$1.40
29 May 2020$1.30
29 Apr 2019$1.25
30 Apr 2018$1.25
02 May 2017$1.20
02 May 2016$1.05